Loading…
AtaiBeckley Inc. is projected to rise to $5.78 by 2027, a +34% move from its current price of $4.32. ATAI is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.19 | $4.32 | $4.45 | +0.01% |
| May 30 | $4.14 | $4.32 | $4.51 | +0.02% |
| May 31 | $4.10 | $4.32 | $4.55 | +0.04% |
| Jun 1 | $4.07 | $4.32 | $4.59 | +0.05% |
| Jun 2 | $4.04 | $4.32 | $4.63 | +0.06% |
| Jun 3 | $4.01 | $4.32 | $4.66 | +0.07% |
| Jun 4 | $3.99 | $4.32 | $4.68 | +0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.99 | $4.32 | $4.68 | +0.08% |
| Week 2 | $3.86 | $4.33 | $4.85 | +0.17% |
| Week 3 | $3.77 | $4.33 | $4.97 | +0.25% |
| Week 4 | $3.69 | $4.33 | $5.09 | +0.33% |
| Week 5 | $3.63 | $4.34 | $5.19 | +0.42% |
| Week 6 | $3.57 | $4.34 | $5.28 | +0.50% |
| Week 7 | $3.52 | $4.35 | $5.37 | +0.59% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AtaiBeckley Inc. is a clinical-stage biopharmaceutical company that engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company is based in New York, New York, and was founded in 2018.
It was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025.
Its portfolio includes BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin, in Phase 2a and 2b for treatment resistant depression and alcohol use disorder; RL-007, an orally bioavailable pro-cognitive neuromodulator in Phase 2b for cognitive impairment associated with schizophrenia; ELE-101, a serotonergic psychedelic for major depressive disorder; VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 to treat TRD; EMP-01 for social anxiety disorder; EGX-A & EGX-B, non-hallucinogenic 5-HT2A receptor agonists for TRD; COMP360 for psilocybin therapy; and GRX-917 for anxiety, depression, and various neurological disorders. The company’s healthcare focus and portfolio reflect its work in mental health treatments across its active regions.
In addition, AtaiBeckley offers COMP360 for psilocybin therapy and GRX-917 for the treatment of anxiety, depression, and various neurological disorders, illustrating a broad development pipeline within its public-facing description.
ATAI is currently trading at $4.32 with a market capitalization of $1.59B, and it holds a global rank of 2182. This position reflects the company’s size within the broader market and its sector.
The forecast presents a rising price trajectory over time. The 2026 forecasted average price is $4.32, and the path forward shows notable upside with the 2030 average at $8.02, the 2040 average at $26.46, and the 2050 average at $58.75. The maximums along the way extend to $12.12 in 2030 and $115.84 in 2050, underscoring a bullish long-term outlook.
These figures are projections and not guarantees, but the long-range view suggests meaningful upside from the current level as the years progress.
A major floor 22.5% below — a decisive break under it would weaken the trend.
The nearest floor, 8.3% below — buyers have tended to step in here.
The nearest ceiling, 13.4% above — a clean break opens room to run.
A major ceiling 23.5% above — clearing it would confirm fresh momentum.
Key ATAI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ATAI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.27 | Buy | $4.26 | Buy |
| MA 10 | $4.18 | Buy | $4.21 | Buy |
| MA 20 | $4.14 | Buy | $4.18 | Buy |
| MA 50 | $3.99 | Buy | $4.08 | Buy |
| MA 100 | $3.91 | Buy | $4.03 | Buy |
| MA 200 | $4.30 | Buy | $3.86 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.97 | Neutral |
| Stoch RSI (14) | 95.40 | Sell |
| CCI (20) | 128.04 | Buy |
| Williams %R (14) | -2.70 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 7.20 | Buy |
| Bollinger %B (20,2) | 0.90 | Neutral |
| Stochastic %K (14) | 97.30 | Sell |
| TRIX (15) | 0.12 | Buy |
| Awesome (5,34) | 0.08 | Buy |
| Ultimate (7,14,28) | 63.39 | Neutral |
| Momentum (10) | 0.17 | Buy |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 4.38 | Sell |
| ADX (14) | 9.85 | Neutral |
| ATR (14) | 0.11 | Info |
The 30-day technical picture is bullish overall, with a current sentiment labeled as BULLISH and an RSI of 60. The stock trades near the SMA50 of $3.97 and the SMA200 of $4.30, indicating modest overlap with the longer-term trend.
Support is noted at $3.79 and resistance at $4.90, framing a near-term trading range. The 30-day range spans from $3.50 to $5.34, offering a window for short-term price movement within those bounds. The stock’s volatility is relatively high, with annualized volatility at 60%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.35 | $4.32 | $6.21 | 0% | Neutral | |
| $4.54 | $5.78 | $7.84 | +34% | Bullish | |
| $4.83 | $6.34 | $8.94 | +47% | Bullish | |
| $5.12 | $6.91 | $10.03 | +60% | Bullish | |
| $5.83 | $8.04 | $11.99 | +86% | Bullish | |
| $6.89 | $9.70 | $14.78 | +124% | Bullish | |
| $8.48 | $12.17 | $18.94 | +182% | Bullish | |
| $9.24 | $13.50 | $21.40 | +213% | Bullish | |
| $9.77 | $14.53 | $23.42 | +236% | Bullish | |
| $10.46 | $15.83 | $25.92 | +266% | Bullish | |
| $16.20 | $26.46 | $46.27 | +512% | Bullish | |
| $31.51 | $58.85 | $113.26 | +12.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.35 | $4.32 | $5.07 | +0.00% |
| June 2026 | $3.61 | $4.25 | $5.13 | -1.69% |
| July 2026 | $3.68 | $4.37 | $5.35 | +2.83% |
| August 2026 | $3.74 | $4.48 | $5.55 | +2.57% |
| September 2026 | $3.68 | $4.43 | $5.55 | -1.00% |
| October 2026 | $3.73 | $4.51 | $5.69 | +1.76% |
| November 2026 | $3.91 | $4.76 | $6.04 | +5.43% |
| December 2026 | $3.97 | $4.85 | $6.21 | +1.99% |
Click any year to see its month-by-month ATAI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ATAI price prediction for 2026 points to an average of $4.32 (low $3.35, high $6.21) — a potential gain of 0% on today's $4.32. Price action looks broadly range-bound.
In 2027, ATAI is projected to trade between $4.54 and $7.84, averaging $5.78 — a potential gain of +34% from today's $4.32. That is up +34% on the projected 2026 average. Buyers look set to stay in control over this stretch.
AtaiBeckley Inc.'s 2028 outlook centres on $6.34, within a $4.83 to $8.94 range. That is up +10% on the projected 2027 average. That marks a +47% change versus current levels. Momentum favours further upside here.
By 2029, ATAI could reach as high as $10.03, with a base case around $6.91 and support toward $5.12 — roughly +60% from $4.32. Buyers look set to stay in control over this stretch.
Expect ATAI to range from $5.83 to $11.99 through 2030. The $8.04 average target implies a +86% move from current prices. That is up +16% on the projected 2029 average. Momentum favours further upside here.
The ATAI price prediction for 2031 points to an average of $9.70 (low $6.89, high $14.78) — a potential gain of +124% on today's $4.32. Buyers look set to stay in control over this stretch.
In 2032, ATAI is projected to trade between $8.48 and $18.94, averaging $12.17 — a potential gain of +182% from today's $4.32. That is up +26% on the projected 2031 average. Momentum favours further upside here.
AtaiBeckley Inc.'s 2033 outlook centres on $13.50, within a $9.24 to $21.40 range. That is up +11% on the projected 2032 average. That marks a +213% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, ATAI could reach as high as $23.42, with a base case around $14.53 and support toward $9.77 — roughly +236% from $4.32. Momentum favours further upside here.
Expect ATAI to range from $10.46 to $25.92 through 2035. The $15.83 average target implies a +266% move from current prices. That is up +9% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The ATAI price prediction for 2040 points to an average of $26.46 (low $16.20, high $46.27) — a potential gain of +512% on today's $4.32. Momentum favours further upside here.
In 2050, ATAI is projected to trade between $31.51 and $113.26, averaging $58.85 — a potential gain of +12.6x from today's $4.32. That is up +122% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ATAI today (≈ 231.481481 ATAI) could be worth
$13,622.15
+$12,622.15 (+1262%) by 2050 · US Dollar
Based on the average projected ATAI price of $58.85 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ATAIwould be worth at today's price.
$1,000 invested in ATAI on May 27, 2025 (≈ 452.48868 ATAI) would be worth
$1,954.75
+$954.75 (+95.5%) today · 1.95× · US Dollar
Based on a ATAI entry price of $2.21 vs. today's $4.32.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.09 | $1,056.23 | +5.6% |
| 1 month ago | $4.34 | $995.39 | -0.5% |
| 3 months ago | $3.73 | $1,158.18 | +15.8% |
| 6 months ago | $3.89 | $1,110.54 | +11.1% |
| 1 year ago | $2.21 | $1,954.75 | +95.5% |
| All time (4.9y) ago | $19.45 | $222.11 | -77.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ATAI forecast.
Our base-case forecast reaches $8.60 around 2031.
Implied market cap at $8.60: $3.17B
2026 marks a neutral start with min $3.35, avg $4.32, max $6.24 and an ROI of 0%. The outlook turns bullish from 2027 onward, with 2027 min $4.51, avg $5.79, max $7.91 and ROI 33.9%; 2028 min $4.80, avg $6.36, max $9.06 and ROI 47.2%; 2029 min $5.00, avg $6.82, max $10.03 and ROI 57.8%; 2030 min $5.74, avg $8.02, max $12.12 and ROI 85.6%.
Looking further, 2031 shows min $6.81, avg $9.72, max $15.05 with ROI 125.1%; 2032 min $8.31, avg $12.12, max $19.16 and ROI 180.5%; 2033 min $9.13, avg $13.58, max $21.88 and ROI 214.3%; 2034 min $9.62, avg $14.58, max $23.91 and ROI 237.4%; 2035 min $10.13, avg $15.64, max $26.07 and ROI 261.9%. The long-range forecast remains bullish, with 2040 min $15.78, avg $26.46, max $47.24 and ROI 512.4%, and 2050 min $30.24, avg $58.75, max $115.84 and ROI 1259.9%.
Overall, these projections imply a substantial upward trajectory over the coming years, though they are estimates and depend on numerous factors affecting the healthcare and biotech sectors.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $8.02, with a min of $5.74 and a max of $12.12, and an estimated ROI of 85.6%. The sentiment is bullish.
The forecast indicates bullish sentiment from 2027 onward, with rising average prices and multiple years showing solid upside (e.g., 2030 average $8.02, 2040 average $26.46, 2050 average $58.75 and higher max values). These are estimates, not guarantees, and market conditions could change.
Yes, the forecast’s max price by 2050 is $115.84, which means a $100 level is within the projected upside in this outlook, though it is not guaranteed.
Current price is $4.32 and market capitalization is $1.59B.
The sentiment is bullish with RSI 60. The SMA50 is $3.97 and SMA200 is $4.30. Support sits at $3.79 and resistance at $4.90, with a 30-day price range of $3.50 to $5.34.
AtaiBeckley Inc. Community Discussion
0Share your AtaiBeckley Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.